1. Karanikas E, Antoniadis D, Garyfallos G. The role of cortisol in first episode of psychosis: a systematic review. Curr Psychiatry Rep 2014;16:503-513. PMID:
25200986.
2. Karanikas E, Garyfallos G. Role of cortisol in patients at risk for psychosis mental state and psychopathological correlates: a systematic review. Psychiatry Clin Neurosci 2015;69:268-282. PMID:
25430397.
3. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-671. PMID:
21641581.
4. Yung AR, Yuen HP, Mc Gorry PD, Phillips LJ, Kelly D, Dell’Olio M, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005;39:964-971. PMID:
16343296.
5. Lykouras E, Botsis A, Oulis P. The Positive and Negative Syndrome Scale (PANSS) [in Greek]. Athens, Greece: Tsiveriotis Ed; 1994.
6. Spelman LM, Walsh P, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 2007;24:481-485. PMID:
17381506.
7. Yildirim O, Dogan O, Semiz M, Kilicli F. Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their firstdegree relatives. Psychiatry Clin Neurosci 2011;65:584-591. PMID:
21895860.
8. Muller N, Schwarz MJ. Immune system and schizophrenia. Curr Immunol Rev 2010;6:213-220. PMID:
21057585.
9. Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, et al. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 2014;41:23-32. PMID:
24495605.
10. Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD, et al. Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull 2015;41:419-428. PMID:
25103207.
11. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002;57:247-258. PMID:
12223256.
12. Dooms H. Interleukin-7: fuel for the autoimmune attack. J Autoimmun 2013;45:40-48. PMID:
23831438.
13. Bradley AJ, Dinan TG. Review: a systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol 2010;24(4 Suppl):91-118.
14. Bose M, Olivan B, Laferrere B. Stress and obesity: the role of the hypothalamic pituitary-adrenal axis in metabolic disease. Curr Opin Endocrinol Diabetes Obes 2009;16:340-346. PMID:
19584720.
15. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005;76:135-157. PMID:
15949648.
16. Di Forti M, Morrison Pd, Butt A, Murray Rm. Cannabis use and psychiatric and cognitive disorders: the chicken or the egg? Curr Opin Psychiatry 2007;20:228-234. PMID:
17415074.
17. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, et al. The inflammatory response system in treatment resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998;32:9-15. PMID:
9690329.
18. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:75-83. PMID:
7708934.
19. Kaminska T, Wysocka A, Marmurowska-Michalowska H, DubasSlemp H, Kandefer-Szerszen M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizo phrenic patients. Arch Immunol Ther Exp (Warsz) 2001;49:439-445. PMID:
11814238.
20. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication naïve and medication-free schizophrenic patients. Neuropsychobiology 2009;59:123-129. PMID:
19390223.
21. Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M, et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 1996;21:39-50. PMID:
8998275.
22. O’Connor MF, Bower JE, Cho HJ, Creswell JD, Dimitrov S, Hamby ME, et al. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun 2009;23:887897